| Phase 4 |
| NCT07093931 |
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2… |
Breast Cancer |
Not Yet Recruiting |
2025-07-30 |
| Phase 3 |
| NCT06850090 |
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102… |
Rectal Cancer |
Recruiting |
2026-10-15 |
| NCT06841172 |
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line… |
OligoProgressive Metastatic Disease |
Recruiting |
2026-10-13 |
| NCT07686640 |
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab… |
Local Advanced Rectal Cancer |
Recruiting |
2026-08-18 |
| NCT07333274 |
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible… |
Head & Neck Squamous Cell Carcinoma |
Recruiting |
2026-01-12 |
| NCT04829708 |
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in… |
Limited Stage Small Cell Lung Cancer |
Recruiting |
2021-04-29 |
| NCT07869524 |
IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma |
Diffuse Intrinsic Pontine Gliomas (DIPG) |
Not Yet Recruiting |
2026-10-09 |
| NCT07869628 |
A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified… |
Newly Diagnosed Triple-negative Breast Cancer |
Not Yet Recruiting |
2026-10-09 |
| NCT06246344 |
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant… |
Rectal Cancer |
Active, Not Recruiting |
2026-09-15 |
| Phase 2 |
| NCT06050317 |
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable… |
Pancreas Cancer |
Recruiting |
2026-10-15 |
| NCT07062055 |
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C… |
Hepatocellular Carcinoma |
Recruiting |
2026-10-15 |
| NCT06778382 |
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary… |
Colorectal Neoplasms Malignant |
Recruiting |
2026-10-13 |
| NCT07026422 |
Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally… |
Rectal Malignant Neoplasms |
Recruiting |
2026-10-13 |
| NCT07173387 |
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer |
Pancreatic Cancer |
Recruiting |
2026-10-13 |
| NCT07683221 |
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally… |
Pancreatic Cancer |
Recruiting |
2026-10-13 |
| NCT07600268 |
Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy… |
Pancreatic Cancer Non-resectable |
Recruiting |
2026-05-20 |
| NCT06356584 |
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of… |
Colorectal Cancer |
Recruiting |
2026-04-28 |
| NCT06532539 |
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma |
Endometrial Neoplasms |
Recruiting |
2026-04-24 |
| NCT06802757 |
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in… |
Breast Cancer |
Recruiting |
2026-02-25 |
| NCT06942416 |
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent… |
Cervical Cancer |
Recruiting |
2025-04-24 |
| NCT06816771 |
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for… |
Rhabdomyosarcoma, Recurrent, Refractory |
Recruiting |
2025-02-10 |
| NCT06241807 |
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC |
IMMUNOTHERAPY |
Recruiting |
2024-02-14 |
| NCT05933967 |
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression… |
The First Affiliated Hospital of Nanchang University |
Recruiting |
2023-08-15 |
| NCT07669051 |
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced… |
NSCLC (Advanced Non-small Cell Lung Cancer) |
Active, Not Recruiting |
2026-06-25 |
| NCT06714266 |
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or… |
Head and Neck Squamous Cell Carcinoma (HNSCC) |
Not Yet Recruiting |
2024-12-03 |